Gilead Sciences
GILD
$67.01
Share price
-0.95%
Change (1 day)
-14.51%
Change (1 year)
Categories
Gilead Sciences (GILD) - P/B ratio
P/B ratio as of May 2024 : 3.67
According to Gilead Sciences's latest financial reports the company has a price-to-book ratio of 3.67.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Gilead Sciences - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 4.44 | -12.6% |
| 2022-12-31 | 5.08 | 17.45% |
| 2021-12-31 | 4.32 | 7.85% |
| 2020-12-31 | 4.01 | 10.35% |
| 2019-12-31 | 3.63 | -2.47% |
| 2018-12-31 | 3.72 | -18.42% |
| 2017-12-31 | 4.56 | -6.31% |
| 2016-12-31 | 4.87 | -35.28% |
| 2015-12-31 | 7.53 | -15.71% |
| 2014-12-31 | 8.93 | -8.96% |
| 2013-12-31 | 9.81 | 67.83% |
| 2012-12-31 | 5.85 | 30.58% |
| 2011-12-31 | 4.48 | -5.7% |
| 2010-12-31 | 4.75 | -20.67% |
| 2009-12-31 | 5.98 | -42.6% |
| 2008-12-31 | 10.4 | -12.16% |
| 2007-12-31 | 11.9 | -25.91% |
| 2006-12-31 | 16.0 | 100.72% |
| 2005-12-31 | 7.98 | -4.91% |
| 2004-12-31 | 8.39 | -32.26% |
| 2003-12-31 | 12.4 | 5.38% |
| 2002-12-31 | 11.8 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.25 | 42.99% | 🇺🇸 USA |
 Pfizer PFE | 1.83 | -50.05% | 🇺🇸 USA |
 AbbVie ABBV | 27.8 | 658.04% | 🇺🇸 USA |
 Eli Lilly LLY | 58.0 | 1,480.33% | 🇺🇸 USA |
 Amgen AMGN | 27.5 | 648.33% | 🇺🇸 USA |
 Biogen BIIB | 2.25 | -38.63% | 🇺🇸 USA |
 Illumina ILMN | 3.19 | -13.10% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | 6.44 | 75.53% | 🇺🇸 USA |
 Merck MRK | 8.91 | 142.76% | 🇺🇸 USA |